A New Hierarchy of Research Evidence for Tumor Pathology: A Delphi Study to Define Levels of Evidence in Tumor Pathology

The hierarchy of evidence is a fundamental concept in evidence-based medicine, but existing models can be challenging to apply in laboratory-based health care disciplines, such as pathology, where the types of evidence and contexts are significantly different from interventional medicine. This project aimed to define a comprehensive and complementary framework of new levels of evidence for evaluating research in tumor pathology-introducing a novel Hierarchy of Research Evidence for Tumor Pathology collaboratively designed by pathologists with help from epidemiologists, public health professionals, oncologists, and scientists, specifically tailored for use by pathologists-and to aid in the production of the World Health Organization Classification of Tumors (WCT) evidence gap maps. To achieve this, we adopted a modified Delphi approach, encompassing iterative online surveys, expert oversight, and external peer review, to establish the criteria for evidence in tumor pathology, determine the optimal structure for the new hierarchy, and ascertain the levels of confidence for each type of evidence. Over a span of 4 months and 3 survey rounds, we collected 1104 survey responses, culminating in a 3-day hybrid meeting in 2023, where a new hierarchy was unanimously agreed upon. The hierarchy is organized into 5 research theme groupings closely aligned with the subheadings of the WCT, and it consists of 5 levels of evidence-level P1 representing evidence types that merit the greatest level of confidence and level P5 reflecting the greatest risk of bias. For the first time, an international collaboration of pathology experts, supported by the International Agency for Research on Cancer, has successfully united to establish a standardized approach for evaluating evidence in tumor pathology. We intend to implement this novel Hierarchy of Research Evidence for Tumor Pathology to map the available evidence, thereby enriching and informing the WCT effectively.

The specific of development tasks in old age

Introduction

The presentation considers the peculiarities of late adulthood, different views on the periodization of older ages (World health organization, I. Burnside, H.S. Pryazhnikov).

Objectives

The research is aimed at studying the peculiarities of late adulthood.

Methods

The method of work is a bibliographic analysis.

Results

Reveals the structure of psychological age (concept by L.S.Vygotsky), the specificity of the development in late adulthood and features of the social situation of development. Reveals modern ideas of ageing as a process not only of involution and loss, but also a process of continued development. The greatest attention is paid to the peculiarities of development tasks at older ages and the difficulties faced by older people trying to cope with them. There are the brief overview of the positions of C.G.Jung, A.Adler, E.Erikson, R.Peck, G.M.Bryugman, A.G.Liders, N.S.Pryazhnikov, E.E.Sapogova, I.V.Shapovalenko, V.I.Slobodchikov, G.A.Zuckerman, etc. regarding the development tasks in late adulthood. The comparison of the development tasks of early and late age periods by G.M. Bryugman, which shows that the tasks of aging worse defined, at least sequentially ordered, and the results of solution of development tasks is less predictable than in earlier ages.

Conclusions

We can say that in old age is important not only the task of adjusting to different changes of pace of life, quality of life, social circle, etc., and overcome the negative aspects of aging but also issues of self-development. As the primary development task in late adulthood is considered an achievement of his own integrity and finding the meaning of life.

Disclosure

No significant relationships.

German-style board games in the mental development of children

Introduction

Play activity has been studied from a scientific point of view relatively recently. Until the middle of the twentieth century, any games were considered only as a way of leisure and/or a tool for transmitting cultural experiences.

Objectives

The research is aimed at studying play activity as a factor of mental development of a child.

Methods

The method of work is a bibliographic analysis.

Results

In psychology, the interest in the role of games in the psychological development of a child is primarily associated with the works of Z. Freud, J. Piaget, L.S. Vygotsky, D.B. Elkonin, who showed the importance of children’s imitation games: role-playing, directing, event-based (classification of E.O. Smirnova).

Since the 90s of the XX century, this hobby is becoming ever more common. At first, modern board games were created by adults for adults, and then there appeared board games specially designed for adults to play with children (family games) and for playing children’s groups.

Most of the board games popular with parents belong to the German school. Such games are characterized by relatively simple rules, a short or medium duration of the game, no direct confrontation between players and a low randomness in the course of the game (for example, Carcassonne, Catan, Ticket to Ride, etc.).

Conclusions

German-style board games develop children’s communication skills, voluntary activity, abstract and formal-logical thinking, symbolic function, attention, the ability to cooperate (in cooperative games), imagination, and many games develop the child’s outlook and enrich the ideas about the world around and options for social interaction.

Disclosure

No significant relationships.

Psychological characteristics of pedagogical activity of scientists

Introduction

Appeal to pedagogical abilities, important for the success of the teacher, allows us to highlight some actual requirements for the scientist.

Objectives

The research is aimed at studying various competencies as a factor of success of the teacher.

Methods

The method of work is a bibliographic analysis.

Results

Firstly, they are communicative abilities, by which are meant the ability to communicate, the ability to find an approach to students, to build trustful dialogue.

Secondly, they are didactic abilities that make it possible to intelligently present the knowledge, stimulate interest in the subject, stimulate students ’cognitive activity, the ability to organize students’ independent work, and form their need for independent knowledge acquisition.

Thirdly, the academic pedagogical abilities of scientists, that is, the abilities for the corresponding field of science, the knowledge of the subject taught, not only in the volume of the training course, but much wider and deeper are the aspect of the necessary pedagogical competencies of scientists.

Fourthly, pedagogical abilities are related to the research orientation of the teacher, with his need and ability to conduct his own research work.

Fifth, among the pedagogical abilities, the pedagogical imagination is distinguished, presupposing the ability to project and predict the development of the student’s actions.

Conclusions

It can be concluded that modern education and society as a whole formed a new request to science and scientists, consisting in the development of their respective pedagogical competences.

Disclosure

No significant relationships.

Using virtual reality to develop emotional intelligence

Introduction

The development of emotional intelligence is an urgent issue of teaching people in our time. The use of a virtual reality (VR) systems for the development of emotional intelligence is a problem of modern pedagogy.

Objectives

The research is aimed at studying interrelations of the level of development of emotional intelligence the manifestations of the ability to perceive and identify emotional expression demonstrated by a virtual avatar in VR CAVE system. The research is aimed at finding unusual ways to develop emotional intelligence.

Methods

The study involved 55 participants aged 18 to 25 years (average age-20.38 ± 0.28), 23 of whom were men and 22 were women. During the study we diagnosed the level of development of emotional intelligence (Sergienko, Vetrova, 2009) and spatial abilities (Rimfeld et al., 2017), type of attachment to the loved one (Sabelnikova, Kashirsky, 2015), and the negotiating style of personality (Soldatova, Gasimov, 2019). In the VR CAVE system, a situation was simulated in which the subject had to detect the avatar and determine the emotional-facial expression displayed by it.

Results

It was shown that the level of respondent’s emotional intelligence development does not determine the success of identifying the avatar’s emotion in VR. The success of identifying emotions depends on the level spatial abilities development. Therefore, it is assumed that in the simulated situation, the avatar is perceived as a special spatial image, and not as a full-fledged partner for interpersonal communication.

Conclusions

Thus, the use of VR systems for training and development of emotional intelligence is not proven.

Disclosure

No significant relationships.

FRI0092 LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY TO TUMOR NECROSIS FACTOR INHIBITORS

Background:

Sarilumab is a human IL-6 receptor (IL-6R) inhibitor approved for the treatment of adults with moderate to severely active rheumatoid arthritis (RA). In the TARGET study (NCT01709578), sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (DMARDs) significantly improved signs and symptoms of RA and physical function versus placebo in patients refractory to tumor necrosis factor (TNF) inhibitors.

Objectives:

Here we report the long-term safety and efficacy of subcutaneous (SC) sarilumab over 5 years in patients who continued treatment in the open-label extension study (OLE), EXTEND (NCT01146652).

Methods:

Patients who received double-blind placebo, sarilumab 150 mg, or sarilumab 200 mg every 2 weeks (q2w) in the 24-week randomized controlled trial (RCT) were eligible to receive open-label sarilumab 200 mg q2w in the OLE, with dose reduction to 150 mg q2w permitted to manage laboratory abnormalities or per investigator’s discretion. Safety outcomes are presented for the OLE population for the follow-up from RCT baseline through OLE cut-off date. Efficacy assessments included Clinical Disease Activity Index (CDAI) score and the proportion of responders (CDAI ≤10 and ≤2.8) over time.

Results:

Of the 546 patients randomized in the RCT, 454 (83%) entered and were treated with sarilumab 200 mg in the OLE (original placebo group n = 156; sarilumab 150 mg n = 145; sarilumab 200 mg n = 153). Demographics and disease characteristics at OLE baseline were similar across groups (mean age 53.2 years; 81% female; mean RA duration [SD] 11.8 years [8.9]). At the time of data cut-off (January 15, 2019), 199/546 (36%) patients had discontinued: 100 (18%), 68 (13%), and 27 (5%) due to treatment-emergent adverse events (AEs), other reasons, and lack of efficacy, respectively. Cumulative exposure to sarilumab through the RCT and OLE (n=521) was 1654.8 patient-years (PY), and 268 patients (51%) had ≥4 years’ exposure. The rates per 100 PY of AEs, serious AEs, AEs leading to discontinuation, and AEs leading to death were 160.4, 10.2, 8.1, and 0.3, respectively. The most common AEs were neutropenia and injection site erythema (15.3 and 11.9 per 100 PY). Absolute neutrophil count <1000 cells/mm3(Grade 3–4 neutropenia) was observed in 74 patients (14.2%) and normalized on treatment in 48 (9.2%). Alanine aminotransferase >3× the upper limit of normal was observed in 46 patients (8.8%) and normalized on treatment in 25 (4.8%). Infections and serious infections occurred at rates of 57.8 and 3.9 per 100 PY, respectively. Clinical efficacy was sustained through 5 years of the OLE (Table). At OLE Week 240 (n = 95) mean change (SD) in CDAI from RCT baseline was −31.2 (14.6).

Table .

Proportion of responders*

Original RCT groupPlacebo +DMARD(n=156)Sarilumab 150 mg +DMARD(n=145)Sarilumab 200 mg +DMARD(n=153)CDAI ≤2.8, n (%) OLE baseline21 (13)26 (18)23 (15) After 192 weeks’ follow-up17 (11)28 (19)28 (18)CDAI ≤10, n (%) OLE baseline62 (40)75 (52)76 (50) After 192 weeks’ follow-up57 (37)61 (42)66 (43)

*Nonresponder imputation

Conclusion:

The safety profile of sarilumab was consistent with results of Phase 3 trials, IL-6R inhibition, and SC administration, and no new safety signals were identified over 5 years of follow-up in patients with RA refractory to TNF inhibitors. Clinical efficacy was sustained through 5 years’ follow-up.

Acknowledgments:

Study funding and medical writing support (Joseph Hodgson, PhD, Adelphi Communications Ltd, Macclesfield, UK) provided by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. in accordance with GPP3 guidelines.

Disclosure of Interests:

Roy Fleischmann Grant/research support from: AbbVie, Akros, Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer, IngelhCentrexion, Eli Lilly, EMD Serono, Genentech, Gilead, Janssen, Merck, Nektar, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Samsung, Sandoz, Sanofi Genzyme, Selecta, Taiho, UCB, Consultant of: AbbVie, ACEA, Amgen, Bristol-Myers Squibb, Eli Lilly, Gilead, GlaxoSmithKline, Novartis, Pfizer, Sanofi Genzyme, UCB, Mark C. Genovese Grant/research support from: Abbvie, Eli Lilly and Company, EMD Merck Serono, Galapagos, Genentech/Roche, Gilead Sciences, Inc., GSK, Novartis, Pfizer Inc., RPharm, Sanofi Genzyme, Consultant of: Abbvie, Eli Lilly and Company, EMD Merck Serono, Genentech/Roche, Gilead Sciences, Inc., GSK, Novartis, RPharm, Sanofi Genzyme, Karina Maslova Shareholder of: Sanofi Genzyme, Employee of: Sanofi Genzyme, Henry Leher Shareholder of: Regeneron Pharmaceuticals, Inc., Employee of: Regeneron Pharmaceuticals, Inc., Amy Praestgaard Employee of: Sanofi Genzyme, Gerd Rüdiger Burmester Consultant of: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Speakers bureau: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma

FRI0108 ASSOCIATION BETWEEN CHANGES IN C-REACTIVE PROTEIN AT WEEK 12 AND PATIENT-REPORTED OUTCOMES AT WEEK 24 WITH SARILUMAB THERAPY ACROSS THREE PIVOTAL PHASE 3 STUDIES

Background:

Evaluation of early response to rheumatoid arthritis (RA) therapy at 12 weeks after initiation is recommended in treatment guidelines. C-reactive protein (CRP) response at 12 weeks on therapy may indicate favorable longer-term patient-reported outcomes (PROs).

Objectives:

To describe the association between CRP response at Week 12 and PROs at Week 24 with sarilumab therapy across three pivotal studies.

Methods:

The analysis included patients with RA who took part in MOBILITY (NCT01061736), TARGET (NCT01709578), or MONARCH (NCT02332590) and were treated with sarilumab 200 mg every 2 weeks (q2w) or adalimumab 40 mg q2w (MONARCH only). Patients who achieved a CRP response at Week 12 (defined as serum CRP ≤3 mg/L) were evaluated for PROs at Week 24. Response for PROs was defined as change from baseline visual analog scale score ≥10 for pain, sleep, and morning stiffness and an increase of ≥4 for FACIT-Fatigue score. Odds ratios (ORs) and 95% confidence intervals (CIs) were generated for the likelihood of achieving PRO responses at Week 24.

Results:

The proportions of patients achieving a CRP response at Week 12 were 78% (MOBILITY), 74% (TARGET), 80% (MONARCH, sarilumab), and 36% (MONARCH, adalimumab). Of these, 71.4% (MOBILITY; OR 3.78, 95% CI 2.31–6.18), 71.5% (TARGET; OR 2.86, 95% CI 1.44–5.65), 79.7% (MONARCH, sarilumab; OR 4.40, 95% CI 2.04–9.47), and 79.7% (MONARCH, adalimumab; OR 2.76, 95% CI 1.36–5.61) reported pain score responses at Week 24. Fatigue responses at Week 24 among Week 12 CRP responders were 66.6% (MOBILITY; OR 2.74, 95% CI 1.69–4.45), 59.9% (TARGET; OR 3.18, 95% CI 1.58–6.42), 73.0% (MONARCH, sarilumab; OR 4.78, 95% CI 2.21–10.33), and 64.1% (MONARCH, adalimumab; OR 1.64, 95% CI 0.88–3.06). Sleep was evaluated in MOBILITY only, and 58.2% of those achieving Week 12 CRP responses reported sleep score responses at Week 24 (OR 3.51, 95% CI 2.10–5.87). Morning stiffness responses (evaluated in TARGET and MONARCH only) at Week 24 among patients with Week 12 CRP responses were 71.5% (TARGET; OR 3.70, 95% CI 1.86–7.39), 81.1% (MONARCH, sarilumab; OR 5.36, 95% CI 2.47–11.63), and 75.0% (MONARCH, adalimumab; OR 2.42, 95% CI 1.24–4.72).

Conclusion:

Achievement of a CRP response at Week 12 in patients with RA treated with sarilumab 200 mg q2w or adalimumab 40 mg q2w was associated with improvements at Week 24 in PROs for pain, fatigue, sleep, and morning stiffness. Among patients with RA, CRP responses at 12 weeks on treatment predict favorable longer-term PRO improvements.

Acknowledgments:

Study funding was provided by Sanofi Genzyme (Cambridge, USA) and Regeneron Pharmaceuticals, Inc. (Tarrytown, USA). Medical writing support (Tracey Lonergan, Adelphi Communications Ltd, Macclesfield, UK) was provided by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. in accordance with Good Publication Practice (GPP3) guidelines.

Disclosure of Interests:

John Tesser Consultant of: Sanofi/Regeneron, Speakers bureau: Sanofi/Regeneron, Grace C. Wright Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Eli Lilly, Myriad Autoimmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, UCB, Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Eli Lilly, Myriad Autoimmune, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, UCB, Vibeke Strand Consultant of: AbbVie, Amgen, Biogen, Celltrion, Consortium of Rheumatology Researchers of North America, Crescendo Bioscience, Eli Lilly, Genentech/Roche, GlaxoSmithKline, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, UCB, Jeff Kaine Speakers bureau: Eli Lilly, Merck, Regeneron Pharmaceuticals, Inc., Sanofi, Karina Maslova Shareholder of: Sanofi Genzyme, Employee of: Sanofi Genzyme, Gregory St John Shareholder of: Regeneron Pharmaceuticals, Inc., Employee of: Regeneron Pharmaceuticals, Inc., Kerri Ford Shareholder of: Sanofi Genzyme, Employee of: Sanofi Genzyme, Amy Praestgaard Employee of: Sanofi Genzyme, Ernest Choy Grant/research support from: Amgen, Bio-Cancer, Chugai Pharma, Ferring Pharmaceuticals, Novimmune, Pfizer, Roche, UCB, Consultant of: AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceuticals, GlaxoSmithKline, Hospita, Ionis, Janssen, Jazz Pharmaceuticals, MedImmune, Merck Sharp & Dohme, Merrimack Pharmaceutical, Napp, Novartis, Novimmune, ObsEva, Pfizer, R-Pharm, Regeneron Pharmaceuticals, Inc., Roche, SynAct Pharma, Sanofi Genzyme, Tonix, UCB, Speakers bureau: Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharma, Eli Lilly, Hospira, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Sanofi-Aventis, UCB

SAT0106 LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH 1 OR >1 PRIOR TUMOR NECROSIS FACTOR INHIBITOR FAILURES

Background:

A proportion of adult patients with rheumatoid arthritis (RA) are refractory to tumor necrosis factor inhibitors (TNFi), and treatment with subsequent biologics is commonly associated with reduced response. Sarilumab is a human IL-6 receptor inhibitor approved for the treatment of adults with moderate to severely active RA. In the Phase 3 TARGET study (NCT01709578), significant improvements in the signs and symptoms of RA and physical function were shown with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) versus placebo in patients refractory to TNFi.

Objectives:

To investigate long-term safety and efficacy of subcutaneous sarilumab over 5 years in patients with 1 or >1 TNFi treatment failure prior to their enrollment in TARGET, who continued onto the open-label extension (OLE) study, EXTEND (NCT01146652).

Methods:

In the 24-week randomized controlled trial (RCT), patients received placebo, sarilumab 150 mg, or sarilumab 200 mg every 2 weeks (q2w), and were eligible to receive open-label sarilumab 200 mg q2w in the OLE. Dose reduction to 150 mg q2w was permitted per investigator’s discretion, or to manage laboratory abnormalities. Safety outcomes are presented for the entire follow-up period from RCT baseline through the OLE. Efficacy was assessed using Clinical Disease Activity Index (CDAI) score.

Results:

Of the 546 patients randomized in the RCT, 454 (83%) entered the OLE, of whom 339 had 1 TNFi failure and 115 had >1 TNFi failure. Patients with >1 TNFi failure were older and had a longer duration of RA than patients with 1 TNFi failure (mean age [SD] 55.3 [12.6] and 52.5 [11.9] years, mean RA duration [SD] 13.9 [9.1] and 11.1 [8.8] years, respectively). Kaplan–Meier estimates of the probability of continuation at 5 years were similar between groups: 48% and 54% for patients with >1 and 1 TNFi failure, respectively. At the time of data cut-off (January 15, 2019) 199/546 patients (36%) had discontinued through the RCT and OLE. The rates per 100 patient-years of treatment-emergent adverse events (AEs) and AEs leading to discontinuation for patients with >1 and 1 TNFi failure were 290.6 and 197.9, and 6.5 and 8.1, respectively. Clinical efficacy of sarilumab was sustained in the OLE through 5 years in both groups, regardless of initial treatment in the RCT (Table).

Table

Mean CDAI and proportion of CDAI responders

Treatment allocation in 24-week RCTPlacebo+DMARDSarilumab 150 mg+DMARDSarilumab 200 mg+DMARD(n=156)(n=145)(n=153)TNFi failures1>11>11>1CDAI, mean (SD)RCT baseline43.7 (12.7)42.5 (10.3)42.0 (13.0)44.3 (13.5)42.1 (13.5)48.5 (13.0)Change after 216 weeks’ follow-up−30.9 (17.5)−32.6 (15.2)−33.3 (15.8)−33.1 (12.7)−30.3 (13.6)−36.0 (18.1)CDAI ≤10, n (%)*OLE baseline48 (42)14 (33)59 (53)16 (47)56 (49)20 (51)After 216 weeks’ follow-up24 (21)10 (24)29 (26)7 (21)29 (25)8 (21)

*Nonresponder imputation

Conclusion:

The long-term safety and efficacy of sarilumab were similar in patients with 1 or >1 prior TNFi failure over 5 years’ follow-up. Clinical efficacy could be sustained through 5 years of treatment.

Acknowledgments:

Study funding and medical writing support (Joseph Hodgson, PhD, Adelphi Communications Ltd, Macclesfield, UK) provided by Sanofi Genzyme (Cambridge, MA, USA) and Regeneron Pharmaceuticals, Inc. (Tarrytown, NJ, USA) in accordance with GPP3 guidelines.

Disclosure of Interests:

Roy Fleischmann Grant/research support from: AbbVie, Akros, Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer, IngelhCentrexion, Eli Lilly, EMD Serono, Genentech, Gilead, Janssen, Merck, Nektar, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Samsung, Sandoz, Sanofi Genzyme, Selecta, Taiho, UCB, Consultant of: AbbVie, ACEA, Amgen, Bristol-Myers Squibb, Eli Lilly, Gilead, GlaxoSmithKline, Novartis, Pfizer, Sanofi Genzyme, UCB, Mark C. Genovese Grant/research support from: Abbvie, Eli Lilly and Company, EMD Merck Serono, Galapagos, Genentech/Roche, Gilead Sciences, Inc., GSK, Novartis, Pfizer Inc., RPharm, Sanofi Genzyme, Consultant of: Abbvie, Eli Lilly and Company, EMD Merck Serono, Genentech/Roche, Gilead Sciences, Inc., GSK, Novartis, RPharm, Sanofi Genzyme, Karina Maslova Shareholder of: Sanofi Genzyme, Employee of: Sanofi Genzyme, Henry Leher Shareholder of: Regeneron Pharmaceuticals, Inc., Employee of: Regeneron Pharmaceuticals, Inc., Amy Praestgaard Employee of: Sanofi Genzyme, Gerd Rüdiger Burmester Consultant of: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Speakers bureau: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma

Fate and transport of radiocesium, radiostrontium and radiocobalt on urban building materials

Kinetics of (137)Cs, (60)Co and (85)Sr sorption on powdered building materials in aqueous suspensions at 20 °C for interaction times of 1, 7, 14 and 28 days were studied. The (137)Cs distribution coefficient (Kd) values for all building materials except limestone practically did not change during 28 days of sorption. The Kd ((85)Sr) was several orders of magnitude lower than for (60)Co. The highest values were observed for asphalt and granite. An effective method to study the radionuclide distribution in depth of building materials using layer-by-layer sanding was developed. Using the developed method, the (137)Cs, (60)Co and (85)Sr distribution with depth of selected building materials at different air humidity, time and temperature was studied. Relative humidity (RH) was found to influence significantly the (85)Sr depth distribution in the case of granite (unlike (137)Cs and (60)Co). While (85)Sr penetrated to 0.5 mm in depth of granite at RH 30%, at RH 87% the depth of (85)Sr penetration to granite reached up to 7 mm.